Entera Bio Ltd. Shareholders Equity (Total)

Shareholders Equity (Total) of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Shareholders Equity (Total) growth rates and interactive chart. Shareholder equity, also referred to as shareholders' equity and stockholders' equity, it a corporation's owners' residual claim after debts have been paid. Equity is equal to a firm's total assets minus its total liabilities. It is found on a company's balance sheet and it's the total equity available to common shareholders (after accounting for preferred equity). Also called book value or net book value.

Highlights and Quick Summary

  • Shareholders Equity (Total) for the quarter ending June 29, 2020 was $7.23 Million (a -27.82% decrease compared to previous quarter)
  • Year-over-year quarterly Shareholders Equity (Total) increased by 79.02%
  • Annual Shareholders Equity (Total) for 2019 was $11.9 Million (a 17.82% increase from previous year)
  • Annual Shareholders Equity (Total) for 2018 was $10.1 Million (a -132.06% decrease from previous year)
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Shareholders Equity (Total) of Entera Bio Ltd.

Most recent Shareholders Equity (Total)of ENTX including historical data for past 10 years.

Interactive Chart of Shareholders Equity (Total) of Entera Bio Ltd.

Entera Bio Ltd. Shareholders Equity (Total) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $7.23 $10.02
2019 $11.92 $4.04 $6.47 $7.66 $11.92
2018 $10.12 $0.0 $0.0 $0.0 $10.12
2017 $-31.56 $-31.56

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.